Gastroparesis-Market Insights, Epidemiology and Market Forecast- 2027

DelveInsight Business Research LLP


Albany, NY -- (SBWIRE) -- 12/21/2018 -- DelveInsight has announced the addition of the "Gastroparesis-Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Gastroparesis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Gastroparesis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Request for sample pages

Gastroparesis is also called delayed gastric emptying. It is a condition that affects the normal spontaneous movement of the muscles (motility) in the stomach. It is defined as a combination of chronic dyspeptic symptoms and delayed emptying of a solid test meal. It remains a difficult-to-treat disorder with a significant impact on quality of life. The signs and symptoms of Gastroparesis may differ among persons with the condition. Symptoms usually occur during and after eating a meal. Characteristic symptoms include: Nausea and/or vomiting, Retching (dry heaves), Stomach fullness after a normal sized meal, Early fullness (satiety).

Gastroparesis is not common. However, the condition affects female more than male population. Out of 100,000 people, about 10 men and about 40 women have gastroparesis. As per National Institute of Health (NIH), people with gastroparesis may have other health problems, such as diabetes, scleroderma, hypothyroidism, multiple sclerosis, amyloidosis and various other problems. While the incidence and prevalence of gastroparesis are not well-defined, according to IFFGD it is estimated to affect up to 5 million individuals in the United States.

According to Digestive Diseases Center, Gastroparesis affects more than 1.5 million Americans, with approximately 100,000 suffering from a severe form of the disorder and standard medical therapy fails to relieve symptoms in approximately 30,000 of these patients. At least 20 percent of people with type 1 diabetes develop gastroparesis. The disease also occurs in people with type 2 diabetes, although less often.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Vanda Pharmaceuticals
2. Takeda Pharmaceutical
3. Allergan
4. Theravance Biopharma
And many others

Drugs covered

1. VLY-686
2. TAK-906
3. Relamorelin
4. TD-8954
And many others

Report Scope

The report covers a descriptive overview of the Gastroparesis, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Gastroparesis disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Gastroparesis are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Gastroparesis market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gastroparesis market